EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed‐methods study

Eve Allen iD, Sona Samadian, Gary Altobelli, Jacinta Johnson, Chris Holmwood

Drug and Alcohol Review · 2023-05 · 42 (4) · 791-802

DOI: 10.1111/dar.13616 ↗

At a glance

Journal article in Drug and Alcohol Review, published online on 2023-02-14. Written by Eve Allen and 4 co-authors. Institution: UniSA Clinical and Health Sciences, University of South Australia, Adelaide, Australia. Major MEDLINE topics: Buprenorphine, Opioid-Related Disorders. Cited 22 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Introduction

The introduction of depot buprenorphine for the treatment of opioid dependence allows for reduced dosing frequency compared with conventional treatments, such as oral methadone and sublingual buprenorphine‐naloxone. Reduced dosing frequency is perceived to reduce issues such as high out‐of‐pocket costs, frequent attendance to pharmacies, stigmatisation and the risk of diversion for unsanctioned opioid use. This study aims to explore the experiences of patients receiving depot buprenorphine from an Australian publicly operated drug and alcohol service.

Methods

Participants were recruited from the service over a 5‐week period in 2021. Twenty‐eight participants consented to be involved in a mixed methods quantitative verbal survey and qualitative interview process.

Results

The majority of participants reported satisfaction with depot buprenorphine across the domains of efficacy, convenience and global satisfaction. Participants perceived benefits as increased convenience, reduced stigmatisation and the inability to ‘skip’ daily Medication Assisted Treatment for Opioid Dependence (MATOD) doses. There were mixed experiences with the ability for depot buprenorphine to ‘hold’ participants throughout the dosing interval. Reduced contact and disconnection from healthcare services were reported as an issue for some participants when initiating depot buprenorphine. Discussion and Conclusions Patient perceptions of depot buprenorphine appear to be deeply rooted in prior experience with ‘conventional’ MATOD treatments. Depot buprenorphine is seen to be beneficial socially, personally, and financially by the majority of patients interviewed. The potential for disconnection from services and mixed experiences of efficacy throughout the dosing period may negatively influence patient experience.

Subjects

MeSH terms (MEDLINE)

BuprenorphineOpioid-Related DisordersHumansOpiate Substitution TreatmentPatient SatisfactionAustraliaMethadoneBuprenorphine, Naloxone Drug CombinationPatient Outcome AssessmentAnalgesics, OpioidNarcotic Antagonists

Author keywords

buprenorphineopiate substitution treatmentopioid-related disordersqualitative researchsocial stigma

Substances

BuprenorphineMethadoneBuprenorphine, Naloxone Drug CombinationAnalgesics, OpioidNarcotic Antagonists

Authors and institutions

  • UniSA Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
  • Drug and Alcohol Services South Australia, SA Health, Adelaide, Australia.
  • SA Pharmacy, Statewide Clinical Support Services, SA Health, Adelaide, Australia.

ORCID profiles: Eve Allen

Cite

APA

Allen, E., Samadian, S., Altobelli, G., Johnson, J., & Holmwood, C. (2023). Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed‐methods study. Drug and Alcohol Review, 42(4), 791-802. https://doi.org/10.1111/dar.13616

Vancouver

Allen E, Samadian S, Altobelli G, Johnson J, Holmwood C. Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed‐methods study. Drug and Alcohol Review. 2023;42(4):791-802. doi:10.1111/dar.13616

BibTeX
@article{Allen2023,
  author = {Allen, Eve and Samadian, Sona and Altobelli, Gary and Johnson, Jacinta and Holmwood, Chris},
  title = {Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed‐methods study},
  journal = {Drug and Alcohol Review},
  year = {2023},
  volume = {42},
  number = {4},
  pages = {791--802},
  doi = {10.1111/dar.13616}
}
Start for free →